Collegium Pharmaceutical Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Collegium Pharmaceutical Inc has an operating margin of 26.9%, meaning the company retains $27 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 29.5% the prior year.
Collegium Pharmaceutical Inc's revenue grew 11.4% year-over-year to $631.4M, a solid pace of expansion. This earns a growth score of 61/100.
Collegium Pharmaceutical Inc has elevated debt relative to equity (D/E of 6.27), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Collegium Pharmaceutical Inc's current ratio of 0.95 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 18/100, which could limit financial flexibility.
Collegium Pharmaceutical Inc converts 32.2% of revenue into free cash flow ($203.3M). This strong cash generation earns a score of 100/100.
Collegium Pharmaceutical Inc earns a strong 30.2% return on equity (ROE), meaning it generates $30 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 24.6% the prior year.
Collegium Pharmaceutical Inc scores 1.16, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.4B) relative to total liabilities ($1.4B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Collegium Pharmaceutical Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Collegium Pharmaceutical Inc generates $2.96 in operating cash flow ($205.0M OCF vs $69.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Collegium Pharmaceutical Inc earns $2.3 in operating income for every $1 of interest expense ($169.9M vs $74.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
This page shows Collegium Pharmaceutical Inc (COLL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Collegium Pharmaceutical Inc generated $631.4M in revenue in fiscal year 2024. This represents an increase of 11.4% from the prior year.
Collegium Pharmaceutical Inc's EBITDA was $173.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.9% from the prior year.
Collegium Pharmaceutical Inc generated $203.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 25.9% from the prior year.
Collegium Pharmaceutical Inc reported $69.2M in net income in fiscal year 2024. This represents an increase of 43.7% from the prior year.
Collegium Pharmaceutical Inc earned $1.86 per diluted share (EPS) in fiscal year 2024. This represents an increase of 44.2% from the prior year.
Collegium Pharmaceutical Inc held $70.6M in cash against $0 in long-term debt as of fiscal year 2024.
Collegium Pharmaceutical Inc had 31M shares outstanding in fiscal year 2024. This represents a decrease of 1.5% from the prior year.
Collegium Pharmaceutical Inc's gross margin was 59.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the prior year.
Collegium Pharmaceutical Inc's operating margin was 26.9% in fiscal year 2024, reflecting core business profitability. This is down 2.5 percentage points from the prior year.
Collegium Pharmaceutical Inc's net profit margin was 11.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 2.5 percentage points from the prior year.
Collegium Pharmaceutical Inc's ROE was 30.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 5.6 percentage points from the prior year.
Collegium Pharmaceutical Inc invested $0 in research and development in fiscal year 2024.
Collegium Pharmaceutical Inc spent $60.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 20.0% from the prior year.
Collegium Pharmaceutical Inc invested $1.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 258.4% from the prior year.
COLL Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $209.4M+11.4% | $188.0M+5.8% | $177.8M-2.3% | $181.9M+14.2% | $159.3M+9.7% | $145.3M+0.2% | $144.9M-3.2% | $149.7M |
| Cost of Revenue | $80.2M+0.7% | $79.6M-1.0% | $80.4M-3.9% | $83.7M+33.8% | $62.5M+14.8% | $54.5M+1.9% | $53.5M-3.0% | $55.1M |
| Gross Profit | $129.2M+19.2% | $108.4M+11.4% | $97.3M-1.0% | $98.3M+1.5% | $96.8M+6.6% | $90.8M-0.7% | $91.5M-3.4% | $94.6M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $67.1M-8.9% | $73.6M-3.6% | $76.4M+21.1% | $63.1M+1.8% | $62.0M+43.0% | $43.3M+3.2% | $42.0M+27.4% | $32.9M |
| Operating Income | $62.1M+76.9% | $35.1M+61.9% | $21.7M-43.1% | $38.1M+9.4% | $34.8M-26.6% | $47.5M-4.0% | $49.5M-19.8% | $61.7M |
| Interest Expense | $21.8M+6.4% | $20.5M-1.6% | $20.8M-8.2% | $22.7M+23.2% | $18.4M+18.0% | $15.6M-10.1% | $17.3M-10.1% | $19.3M |
| Income Tax | $11.9M+136.6% | $5.0M+615.2% | $705K-85.1% | $4.7M-24.2% | $6.2M-34.2% | $9.5M+6.5% | $8.9M-39.7% | $14.8M |
| Net Income | $31.5M+162.9% | $12.0M+395.8% | $2.4M-80.7% | $12.5M+34.3% | $9.3M-52.4% | $19.6M-29.3% | $27.7M-13.2% | $31.9M |
| EPS (Diluted) | $0.84+147.1% | $0.34+385.7% | $0.07-80.6% | $0.36+33.3% | $0.27-48.1% | $0.52-26.8% | $0.71-13.4% | $0.82 |
COLL Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B+0.9% | $1.6B-2.4% | $1.6B-1.9% | $1.7B+1.7% | $1.6B+55.2% | $1.1B-5.5% | $1.1B-2.5% | $1.1B |
| Current Assets | $613.9M+11.8% | $549.2M+4.1% | $527.6M+9.4% | $482.3M+8.7% | $443.8M-13.0% | $510.2M-5.4% | $539.3M+0.3% | $537.6M |
| Cash & Equivalents | $150.1M+27.9% | $117.3M+22.0% | $96.2M+36.3% | $70.6M+81.1% | $39.0M-77.5% | $172.9M-24.4% | $228.6M-4.3% | $238.9M |
| Inventory | $38.1M-0.3% | $38.1M+2.5% | $37.2M+4.7% | $35.6M-6.5% | $38.0M+36.5% | $27.9M-10.9% | $31.3M-3.3% | $32.3M |
| Accounts Receivable | $233.9M+9.8% | $213.0M-6.9% | $228.7M+0.1% | $228.5M0.0% | $228.5M+24.3% | $183.9M+5.2% | $174.7M-2.7% | $179.5M |
| Goodwill | $145.9M-1.4% | $147.9M-1.9% | $150.8M-7.1% | $162.3M+11.2% | $146.0M+9.0% | $133.9M0.0% | $133.9M0.0% | $133.9M |
| Total Liabilities | $1.3B-2.1% | $1.4B-2.6% | $1.4B-2.6% | $1.4B+2.4% | $1.4B+67.4% | $836.8M-6.2% | $892.1M-5.9% | $947.9M |
| Current Liabilities | $452.9M-2.5% | $464.6M-4.5% | $486.7M-4.5% | $509.5M+10.9% | $459.4M-0.5% | $461.7M+3.4% | $446.4M-2.5% | $457.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $274.8M+18.3% | $232.2M-1.0% | $234.4M+2.4% | $228.8M-2.3% | $234.3M+8.2% | $216.6M-2.5% | $222.2M+13.7% | $195.4M |
| Retained Earnings | -$118.1M+21.1% | -$149.6M+7.4% | -$161.6M+1.5% | -$164.0M+7.1% | -$176.5M+5.0% | -$185.9M+9.5% | -$205.5M+11.9% | -$233.2M |
COLL Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $78.4M+8.3% | $72.4M+30.8% | $55.4M-34.6% | $84.6M+1040.6% | -$9.0M-113.4% | $67.4M+8.8% | $61.9M-15.5% | $73.3M |
| Capital Expenditures | $188K+189.2% | $65K-91.9% | $798K+40.0% | $570K+133.6% | $244K-9.6% | $270K-52.5% | $568K+246.3% | $164K |
| Free Cash Flow | $78.3M+8.1% | $72.4M+32.6% | $54.6M-35.1% | $84.1M+1009.6% | -$9.2M-113.8% | $67.1M+9.4% | $61.4M-16.1% | $73.2M |
| Investing Cash Flow | -$30.9M-958.9% | -$2.9M+69.9% | -$9.7M+17.7% | -$11.8M+95.3% | -$249.0M-2695.5% | -$8.9M+50.9% | -$18.1M+27.8% | -$25.1M |
| Financing Cash Flow | -$14.8M+69.4% | -$48.4M-91.7% | -$25.2M+38.9% | -$41.3M-127.7% | $149.0M+230.5% | -$114.2M-110.9% | -$54.1M+20.2% | -$67.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | N/A | N/A | $25.0M | $0 | N/A | N/A | $25.0M |
COLL Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.7%+4.0pp | 57.6%+2.9pp | 54.8%+0.7pp | 54.0%-6.7pp | 60.8%-1.7pp | 62.5%-0.6pp | 63.1%-0.1pp | 63.2% |
| Operating Margin | 29.7%+11.0pp | 18.7%+6.5pp | 12.2%-8.8pp | 20.9%-0.9pp | 21.9%-10.8pp | 32.7%-1.5pp | 34.1%-7.1pp | 41.2% |
| Net Margin | 15.0%+8.7pp | 6.4%+5.0pp | 1.4%-5.5pp | 6.9%+1.0pp | 5.9%-7.6pp | 13.5%-5.6pp | 19.1%-2.2pp | 21.3% |
| Return on Equity | 11.5%+6.3pp | 5.2%+4.1pp | 1.0%-4.5pp | 5.5%+1.5pp | 4.0%-5.1pp | 9.0%-3.4pp | 12.5%-3.9pp | 16.3% |
| Return on Assets | 2.0%+1.2pp | 0.8%+0.6pp | 0.1%-0.6pp | 0.8%+0.2pp | 0.6%-1.3pp | 1.9%-0.6pp | 2.5%-0.3pp | 2.8% |
| Current Ratio | 1.36+0.2 | 1.18+0.1 | 1.08+0.1 | 0.95-0.0 | 0.97-0.1 | 1.10-0.1 | 1.21+0.0 | 1.17 |
| Debt-to-Equity | 4.85-1.0 | 5.86-0.1 | 5.96-0.3 | 6.27+0.3 | 5.98+2.1 | 3.86-0.2 | 4.02-0.8 | 4.85 |
| FCF Margin | 37.4%-1.1pp | 38.5%+7.8pp | 30.7%-15.5pp | 46.2%+52.0pp | -5.8%-52.0pp | 46.2%+3.9pp | 42.4%-6.5pp | 48.9% |
Note: The current ratio is below 1.0 (0.95), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Collegium Pharmaceutical Inc's annual revenue?
Collegium Pharmaceutical Inc (COLL) reported $631.4M in total revenue for fiscal year 2024. This represents a 11.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Collegium Pharmaceutical Inc's revenue growing?
Collegium Pharmaceutical Inc (COLL) revenue grew by 11.4% year-over-year, from $566.8M to $631.4M in fiscal year 2024.
Is Collegium Pharmaceutical Inc profitable?
Yes, Collegium Pharmaceutical Inc (COLL) reported a net income of $69.2M in fiscal year 2024, with a net profit margin of 11.0%.
What is Collegium Pharmaceutical Inc's earnings per share (EPS)?
Collegium Pharmaceutical Inc (COLL) reported diluted earnings per share of $1.86 for fiscal year 2024. This represents a 44.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Collegium Pharmaceutical Inc's EBITDA?
Collegium Pharmaceutical Inc (COLL) had EBITDA of $173.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Collegium Pharmaceutical Inc's gross margin?
Collegium Pharmaceutical Inc (COLL) had a gross margin of 59.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Collegium Pharmaceutical Inc's operating margin?
Collegium Pharmaceutical Inc (COLL) had an operating margin of 26.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Collegium Pharmaceutical Inc's net profit margin?
Collegium Pharmaceutical Inc (COLL) had a net profit margin of 11.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Collegium Pharmaceutical Inc's return on equity (ROE)?
Collegium Pharmaceutical Inc (COLL) has a return on equity of 30.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Collegium Pharmaceutical Inc's free cash flow?
Collegium Pharmaceutical Inc (COLL) generated $203.3M in free cash flow during fiscal year 2024. This represents a -25.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Collegium Pharmaceutical Inc's operating cash flow?
Collegium Pharmaceutical Inc (COLL) generated $205.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Collegium Pharmaceutical Inc's total assets?
Collegium Pharmaceutical Inc (COLL) had $1.7B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Collegium Pharmaceutical Inc's capital expenditures?
Collegium Pharmaceutical Inc (COLL) invested $1.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
Does Collegium Pharmaceutical Inc buy back shares?
Yes, Collegium Pharmaceutical Inc (COLL) spent $60.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Collegium Pharmaceutical Inc have outstanding?
Collegium Pharmaceutical Inc (COLL) had 31M shares outstanding as of fiscal year 2024.
What is Collegium Pharmaceutical Inc's current ratio?
Collegium Pharmaceutical Inc (COLL) had a current ratio of 0.95 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Collegium Pharmaceutical Inc's debt-to-equity ratio?
Collegium Pharmaceutical Inc (COLL) had a debt-to-equity ratio of 6.27 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Collegium Pharmaceutical Inc's return on assets (ROA)?
Collegium Pharmaceutical Inc (COLL) had a return on assets of 4.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Collegium Pharmaceutical Inc's Altman Z-Score?
Collegium Pharmaceutical Inc (COLL) has an Altman Z-Score of 1.16, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Collegium Pharmaceutical Inc's Piotroski F-Score?
Collegium Pharmaceutical Inc (COLL) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Collegium Pharmaceutical Inc's earnings high quality?
Collegium Pharmaceutical Inc (COLL) has an earnings quality ratio of 2.96x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Collegium Pharmaceutical Inc cover its interest payments?
Collegium Pharmaceutical Inc (COLL) has an interest coverage ratio of 2.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Collegium Pharmaceutical Inc?
Collegium Pharmaceutical Inc (COLL) scores 63 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.